Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Andrea Galbiati; Paulina Dorten; Ettore Gilardoni; Florian Gierse; Matilde Bocci; Aureliano Zana; Jacqueline Mock; Michael Claesener; Juela Cufe; Florian Büther; Klaus Schäfers; Sven Hermann; Michael Schäfers; Dario Neri; Samuele Cazzamalli; Philipp Backhaus

doi:10.2967/jnumed.123.266007

Research ArticleBasic Science Investigation

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Andrea Galbiati, Paulina Dorten, Ettore Gilardoni, Florian Gierse, Matilde Bocci, Aureliano Zana, Jacqueline Mock, Michael Claesener, Juela Cufe, Florian Büther, Klaus Schäfers, Sven Hermann, Michael Schäfers, Dario Neri, Samuele Cazzamalli and Philipp Backhaus

Journal of Nuclear Medicine December 2023, 64 (12) 1934-1940; DOI: https://doi.org/10.2967/jnumed.123.266007

Andrea Galbiati

1Research and Development Department, Philochem AG, Otelfingen, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paulina Dorten

2European Institute for Molecular Imaging, University of Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ettore Gilardoni

1Research and Development Department, Philochem AG, Otelfingen, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Florian Gierse

2European Institute for Molecular Imaging, University of Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matilde Bocci

1Research and Development Department, Philochem AG, Otelfingen, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Aureliano Zana

1Research and Development Department, Philochem AG, Otelfingen, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacqueline Mock

1Research and Development Department, Philochem AG, Otelfingen, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Claesener

3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Juela Cufe

2European Institute for Molecular Imaging, University of Münster, Münster, Germany;

3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Florian Büther

3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Klaus Schäfers

2European Institute for Molecular Imaging, University of Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sven Hermann

2European Institute for Molecular Imaging, University of Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Schäfers

2European Institute for Molecular Imaging, University of Münster, Münster, Germany;

3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;

4West German Cancer Centre, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dario Neri

5Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and

6Philogen S.p.A., Siena, Italy

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Samuele Cazzamalli

1Research and Development Department, Philochem AG, Otelfingen, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Philipp Backhaus

2European Institute for Molecular Imaging, University of Münster, Münster, Germany;

3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;

4West German Cancer Centre, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 12

December 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Journal of Nuclear Medicine Dec 2023, 64 (12) 1934-1940; DOI: 10.2967/jnumed.123.266007

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Journal of Nuclear Medicine Dec 2023, 64 (12) 1934-1940; DOI: 10.2967/jnumed.123.266007

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors

Google Scholar

Keywords

combination therapies
fibroblast activation protein
immunocytokines
radioligand therapeutics
tumor targeting

Main menu

User menu

Search

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords